{"id":62118,"date":"2026-04-01T21:26:56","date_gmt":"2026-04-01T13:26:56","guid":{"rendered":"https:\/\/flcube.com\/?p=62118"},"modified":"2026-04-01T21:26:57","modified_gmt":"2026-04-01T13:26:57","slug":"gilead-and-galapagos-forge-2-175-billion-t-cell-engager-collaboration-for-autoimmune-diseases-following-ouro-medicines-acquisition","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62118","title":{"rendered":"Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition"},"content":{"rendered":"\n<p><strong>Gilead Sciences Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GILD:NASDAQ\">NASDAQ: GILD<\/a>) and <strong>Galapagos NV<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/GLPG:NASDAQ\">NASDAQ: GLPG<\/a>) announced a comprehensive collaboration to advance <strong>T-cell engagers (TCEs)<\/strong> for autoimmune diseases, directly linked to Gilead&#8217;s <strong>$2.175 billion acquisition<\/strong> of <strong>Ouro Medicines<\/strong>, with Galapagos assuming 50% of acquisition costs and gaining access to multiple preclinical programs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Ouro Medicines Acquisition<\/strong><\/td><td>Up to USD 2.175 billion total value<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 1.675 billion<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>USD 500 million potential additional payments<\/td><\/tr><tr><td><strong>Galapagos Cost Share<\/strong><\/td><td>50% of total acquisition costs<\/td><\/tr><tr><td><strong>Additional Milestones<\/strong><\/td><td>Up to USD 100 million for registrational trial initiation<\/td><\/tr><tr><td><strong>Royalty Rate<\/strong><\/td><td>Tiered 20-23% on net sales<\/td><\/tr><tr><td><strong>Preclinical Program Options<\/strong><\/td><td>Three additional autoimmune programs at USD 75 million each<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lead-asset-gamgertamig-bcma-cd3-tce\">Lead Asset \u2013 Gamgertamig (BCMA\u00d7CD3 TCE)<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-status\">Development Status<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stage<\/strong>: Clinical-stage T-cell engager<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Depletes B cells and plasma cells via BCMA\u00d7CD3 targeting<\/li>\n\n\n\n<li><strong>Indications<\/strong>: Severe autoimmune diseases<\/li>\n\n\n\n<li><strong>Regulatory Designations<\/strong>:<\/li>\n\n\n\n<li>FDA Fast Track designation for AIHA and ITP<\/li>\n\n\n\n<li>FDA Orphan Drug designation for AIHA and ITP<\/li>\n\n\n\n<li><strong>Registrational Timeline<\/strong>: Expected to begin as early as 2027<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-arrangement\">Commercial Arrangement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Rights<\/strong>: Gilead responsible for worldwide commercialization<\/li>\n\n\n\n<li><strong>Royalty Structure<\/strong>: Galapagos receives tiered royalties (20-23%) on net sales<\/li>\n\n\n\n<li><strong>Milestone Eligibility<\/strong>: Additional USD 100 million contingent on registrational trial initiation in new indications<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-additional-preclinical-programs\">Additional Preclinical Programs<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Number of Programs<\/strong>: Three preclinical TCE programs targeting autoimmune diseases<\/li>\n\n\n\n<li><strong>Access Terms<\/strong>: Galapagos gains immediate access to all three programs<\/li>\n\n\n\n<li><strong>Co-Development Option<\/strong>: Gilead can opt into 50\/50 profit-sharing after proof-of-concept<\/li>\n\n\n\n<li><strong>Exercise Price<\/strong>: USD 75 million per program upon option exercise<\/li>\n\n\n\n<li><strong>Strategic Value<\/strong>: Expands pipeline beyond lead asset gamgertamig<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-gilead-sciences\">For Gilead Sciences<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autoimmune Expansion<\/strong>: Diversifies beyond virology and oncology into high-value autoimmune market<\/li>\n\n\n\n<li><strong>TCE Platform<\/strong>: Establishes presence in emerging T-cell engager therapeutic class<\/li>\n\n\n\n<li><strong>Risk Sharing<\/strong>: Partners with Galapagos to share substantial acquisition costs<\/li>\n\n\n\n<li><strong>Pipeline Depth<\/strong>: Gains access to multiple clinical and preclinical assets through single transaction<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-galapagos\">For Galapagos<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cost Efficiency<\/strong>: Shares significant acquisition burden while gaining substantial asset access<\/li>\n\n\n\n<li><strong>Revenue Diversification<\/strong>: Multiple revenue streams from royalties, milestones, and potential co-development<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Validates TCE approach in autoimmune diseases through major pharma partnership<\/li>\n\n\n\n<li><strong>Financial Leverage<\/strong>: Limited upfront investment with substantial upside potential<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Autoimmune Market<\/strong>: Global autoimmune therapeutics market exceeds $150 billion annually<\/li>\n\n\n\n<li><strong>T-Cell Engager Innovation<\/strong>: Novel application of TCE technology beyond oncology into autoimmune diseases<\/li>\n\n\n\n<li><strong>B-Cell Depletion Strategy<\/strong>: Competes with established anti-CD20 therapies but offers more comprehensive plasma cell targeting<\/li>\n\n\n\n<li><strong>Regulatory Advantages<\/strong>: Fast Track and Orphan designations accelerate development timeline and provide market exclusivity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gilead Investment<\/strong>: Substantial upfront commitment with shared risk structure<\/li>\n\n\n\n<li><strong>Galapagos Exposure<\/strong>: Limited financial risk with significant milestone and royalty upside<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: Multi-billion dollar peak sales potential across multiple autoimmune indications<\/li>\n\n\n\n<li><strong>Development Costs<\/strong>: Shared burden reduces individual company risk exposure<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the collaboration agreement, clinical development, and financial terms. Actual results may differ due to risks including regulatory approvals, clinical trial outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) announced a comprehensive collaboration to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4410,226,1025,4670],"class_list":["post-62118","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-galapagos","tag-gilead-sciences","tag-nasdaq-gild","tag-nasdaq-glpg"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Gilead Sciences Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) announced a comprehensive collaboration to advance T-cell engagers (TCEs) for autoimmune diseases, directly linked to Gilead&#039;s $2.175 billion acquisition of Ouro Medicines, with Galapagos assuming 50% of acquisition costs and gaining access to multiple preclinical programs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62118\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) announced a comprehensive collaboration to advance T-cell engagers (TCEs) for autoimmune diseases, directly linked to Gilead&#039;s $2.175 billion acquisition of Ouro Medicines, with Galapagos assuming 50% of acquisition costs and gaining access to multiple preclinical programs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62118\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T13:26:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-01T13:26:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62118#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62118\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition\",\"datePublished\":\"2026-04-01T13:26:56+00:00\",\"dateModified\":\"2026-04-01T13:26:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62118\"},\"wordCount\":482,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Galapagos\",\"Gilead Sciences\",\"NASDAQ: GILD\",\"NASDAQ: GLPG\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62118#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62118\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62118\",\"name\":\"Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-01T13:26:56+00:00\",\"dateModified\":\"2026-04-01T13:26:57+00:00\",\"description\":\"Gilead Sciences Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) announced a comprehensive collaboration to advance T-cell engagers (TCEs) for autoimmune diseases, directly linked to Gilead's $2.175 billion acquisition of Ouro Medicines, with Galapagos assuming 50% of acquisition costs and gaining access to multiple preclinical programs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62118#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62118\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62118#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition - Insight, China&#039;s Pharmaceutical Industry","description":"Gilead Sciences Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) announced a comprehensive collaboration to advance T-cell engagers (TCEs) for autoimmune diseases, directly linked to Gilead's $2.175 billion acquisition of Ouro Medicines, with Galapagos assuming 50% of acquisition costs and gaining access to multiple preclinical programs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62118","og_locale":"en_US","og_type":"article","og_title":"Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition","og_description":"Gilead Sciences Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) announced a comprehensive collaboration to advance T-cell engagers (TCEs) for autoimmune diseases, directly linked to Gilead's $2.175 billion acquisition of Ouro Medicines, with Galapagos assuming 50% of acquisition costs and gaining access to multiple preclinical programs.","og_url":"https:\/\/flcube.com\/?p=62118","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-01T13:26:56+00:00","article_modified_time":"2026-04-01T13:26:57+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62118#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62118"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition","datePublished":"2026-04-01T13:26:56+00:00","dateModified":"2026-04-01T13:26:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62118"},"wordCount":482,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Galapagos","Gilead Sciences","NASDAQ: GILD","NASDAQ: GLPG"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62118#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62118","url":"https:\/\/flcube.com\/?p=62118","name":"Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-01T13:26:56+00:00","dateModified":"2026-04-01T13:26:57+00:00","description":"Gilead Sciences Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) announced a comprehensive collaboration to advance T-cell engagers (TCEs) for autoimmune diseases, directly linked to Gilead's $2.175 billion acquisition of Ouro Medicines, with Galapagos assuming 50% of acquisition costs and gaining access to multiple preclinical programs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62118#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62118"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62118#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62118","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62118"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62118\/revisions"}],"predecessor-version":[{"id":62120,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62118\/revisions\/62120"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62118"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62118"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62118"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}